Many Health Plans Now Must Cover Full Cost of Expensive HIV Prevention Drugs
Starting this month, most people with private insurance will no longer have to decide whether they can afford to protect themselves against HIV.
Starting this month, most people with private insurance will no longer have to decide whether they can afford to protect themselves against HIV.
This article is for premium subscribers. Please sign up here for a tax-deductible subscription.
If you're a premium subscriber, sign in below.
The state released its latest drug transparency data, which shows that Humira, used for rheumatoid arthritis, racked up $81 million in sales over the past year.
Health insurance companies will have to give their customers estimated out-of-pocket costs for prescription drugs and disclose to the public the negotiated prices they pay for drugs.
If they’ve been listening to President Donald Trump, seniors may be expecting a $200 debit card in the mail any day now to help them pay for prescription drugs.
This article is for premium subscribers. Please sign up here for a tax-deductible subscription.
If you're a premium subscriber, sign in below.
The pharmaceutical industry has donated nearly $280,000 to state lawmakers and candidates in Oregon since the start of 2019, with five Republicans drawing the biggest sums.
Though Florida and five other states -- not in the Northwest -- have passed laws allowing them to seek federal approval to buy drugs from Canada, observers say the proposal is aimed at Florida.
The Food and Drug Administration is weighing whether to resume a coronavirus vaccine trial that was halted when a volunteer suffered spinal cord damage as federal health officials launch an investigation.
Given the prevailing business-centric model of American drug pricing, a COVID-19 vaccine could be budget breaking, perhaps making it unavailable to many.
Advocates say a new rule will make it harder for patients with conditions such as cancer and multiple sclerosis who rely on very expensive drugs to afford them.
At the end of September, Amarin Corp. teased some early findings for Vascepa, its preventive medicine for people at risk of heart disease. The claim was astounding: a 25 percent relative risk reduction for deaths related to heart attacks, strokes and other conditions.